AU Patent

AU2020202684A1 — Dosing regimen for a selective S1P1 receptor agonist

Assigned to Actelion Pharmaceuticals Ltd · Expires 2020-05-14 · 6y expired

What this patent protects

: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

USPTO Abstract

: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

Drugs covered by this patent

Patent Metadata

Patent number: AU2020202684A1
Jurisdiction: AU
Classification: —
Expires: 2020-05-14
Drug substance claim: No
Drug product claim: No
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.